References
- Ma D, Chen CB, Jhanji V, et al. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. Eye. 2020;34:1212–1219. doi:https://doi.org/10.1038/s41433-020-0939-4.
- Aiello F, Gallo Afflitto G, Mancino R, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. Eye (Lond). 2020 Jul;34(7):1206–1211. doi:https://doi.org/10.1038/s41433-020-0926-9.
- Aggarwal K, Agarwal A, Jaiswal N, et al. Ocular surface manifestations of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. PLoS One. 2020 Nov 5;15(11):e0241661. doi:https://doi.org/10.1371/journal.pone.0241661.
- Important coronavirus context for ophthalmologists. American Academy of Ophthalmology. ONE Network. 2020. https://www.aao.org/headline/alert-important-coronavirus-context. Accessed July 12, 2021.
- Flangan JL, Wilcox MD. Role of lactoferrin in tear film. Biochimie. 2009;91:35–43. doi:https://doi.org/10.1016/j.biochi.2008.07.007.
- Vagge A, Senni C, Bernabei F, et al. Therapeutic effects of lactoferrin in ocular diseases: from dry eye disease to infections. Int J Mol Sci. 2020 Sep;21(18):6668. doi:https://doi.org/10.3390/ijms21186668.
- Hara K, Ikeda M, Saito S, et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. 2002;24(3):228. doi:https://doi.org/10.1016/s1386-6346(02)00088-8.
- Seganti L, Di Biase AM, Marchetti M, et al. Antiviral activity of lactoferrin towards naked viruses. Biometals. 2004;17(3):295–299. doi:https://doi.org/10.1023/b:biom.0000027708.27142.bc.
- Rosa L, Cutone A, Lepanto MS, Paesano R, Valenti P. Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci. 2017;18(9):1985. doi:https://doi.org/10.3390/ijms18091985.
- Anderssen JH, Jenssen H, Sandvik K, Gutteberg TJ. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J Med Virol. 2004;74:262–271. doi:https://doi.org/10.1002/jmv.20171.
- Waarts BL, Aneke OJ, Smit JM, et al. Antiviral activity of human lactoferrin: inhibition of alphavirus interaction with heparan sulfate. Virology. 2005;333(2):284–292. doi:https://doi.org/10.1016/j.virol.2005.01.010.
- Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710. doi:https://doi.org/10.1371/journal.pone.0023710.
- Milewska A, Nowak P, Owczarek K, et al. Entry of human coronavirus NL63 into the cell. J Virol. 2018 17;92(3):e01933–17. doi:https://doi.org/10.1128/JVI.01933-17.
- Zhang Q, Chen CZ, Swaroop M, et al. Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov. 2020 4;6(1):80. doi:https://doi.org/10.1038/s41421-020-00222-5.
- Wang Y, Wang P, Wang H, et al. Lactoferrin for the treatment of COVID-19 (Review). Exp Ther Med. 2020 Dec;20(6):272. doi:https://doi.org/10.3892/etm.2020.9402.
- Cutone A, Rosa L, Lepanto MS, et al. Lactoferrin efficiently counteracts the inflammation-induced changes of the iron homeostasis system in macrophages. Front Immunol. 2017;15(8):705. doi:https://doi.org/10.3389/fimmu.2017.00705.